FDA approves GSK vaccine to combat meningococcal infections
Meningococcal infections can lead to severe, sometimes deadly, bloodstream infections, and severe swelling in the brain and ...
Here's Why We're Wary Of Buying GSK's (LON:GSK) For Its Upcoming Dividend
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might ...
Here’s the dividend forecast for GSK shares through to 2026!
City brokers expect dividends on GSK shares will keep marching higher. Is the FTSE 100 share a top passive income stock to ...
US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...
FiercePharma13h
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
ROSEN, A LEADING NATIONAL FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Rosen Law Firm PAWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers ...
GSK Q3FY25 Results: Net profit jumps 4X to ₹229 crore; revenue improves 18%
GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...
Hedge fund Citadel takes short position in GSK, FT reports
Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...
GlaxoSmithKline Pharma Q3 results: Net profit up five-fold at Rs 229 crore
GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased over five-fold to Rs 229 crore for the third quarter ended December 31, 2024.
Nabors Energy Transition Corp. II to take energy-focused tech company public
Houston-based Nabors Energy Transition Corp. II (Nasdaq: NETD), a special purpose acquisition company, will merge with Florida-based e2Companies LLC, which provides solutions for on-site power ...
The Financial Express1d
Q3 Results 2025 Live Updates: Parle Industries, Bajaj Consumer, ABFRL, Glenmark Pharma, others releasing Q3 results today
Today, majors across segments including Parle Industries, Easy Trip Planners, Bajaj Consumer Care, Aditya Birla Fashion & ...